Bicycle Therapeutics PLC (BCYC) ニュース

Bicycle Therapeutics Presents Updated Clinical Results Across Oncology Pipeline at ESMO Congress 2024

Updated monotherapy data for Nectin-4 targeting zelenectide pevedotin in metastatic urothelial cancer (mUC) showed a promising 45% overall...

Bicycle Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Bicycle Therapeutics plc (NASDAQ: BCYC), today announced that on September 3, 2024, the Compensation Committee of the company’s Board of...

Bicycle Therapeutics to Participate in Upcoming Investor Conferences

Bicycle Therapeutics plc (NASDAQ: BCYC), a pharmaceutical company pioneering a new and differentiated class of therapeutics based on its...

Form S-8 - Securities to be offered to employees in employee benefit plans

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Form 8-K - Current report

Bicycle Therapeutics Reports Recent Business Progress and Second Quarter 2024 Financial Results

Four abstracts containing data updates across clinical pipeline accepted for poster presentation at ESMO Congress 2024 Focused R&D pipeline...

Bicycle Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Bicycle Therapeutics plc (NASDAQ: BCYC) today announced that on August 1, 2024, the Compensation Committee of the company’s Board of Directors...

Bicycle Therapeutics Announces Four Abstracts Accepted for Presentation at the ESMO Congress 2024

Bicycle Therapeutics plc (NASDAQ: BCYC), a pharmaceutical company pioneering a new and differentiated class of therapeutics based on its...

Form 8-K - Current report

Form 4 - Statement of changes in beneficial ownership of securities

Form 4 - Statement of changes in beneficial ownership of securities

Form 4 - Statement of changes in beneficial ownership of securities

Form 4 - Statement of changes in beneficial ownership of securities

Form 4 - Statement of changes in beneficial ownership of securities